Ly James Lee
Ohio State University
66 Papers
551 Citations
Ly James Lee is an academic researcher from Ohio State University. The author has contributed to research in topics: Electroporation & Leukemia. The author has an hindex of 24, co-authored 64 publications.
Chat about Author
Papers
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
Xiaomeng Huang,Sebastian Schwind,Bo Yu,Ramasamy Santhanam,Hongyan Wang,Pia Hoellerbauer,Alice S. Mims,Rebecca B. Klisovic,Alison Walker,Kenneth K. Chan,William Blum,Danilo Perrotti,John C. Byrd,Clara D. Bloomfield,Michael A. Caligiuri,Robert J. Lee,Ramiro Garzon,Natarajan Muthusamy,Ly James Lee,Guido Marcucci +19 more
TL;DR: Tf-NP effectively delivered functional miR-29b, resulting in target downregulation and antileukemic activity and warrants further investigation as a novel therapeutic approach in AML.
181
Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy.
Yi You,Yupeng Tian,Zhaogang Yang,Junfeng Shi,Kwang Joo Kwak,Yuhao Tong,Andreanne Poppy Estania,Jianhong Cao,Wei-Hsiang Hsu,Yutong Liu,Chi-Ling Chiang,Benjamin R. Schrank,Kristin Huntoon,DaeYong Lee,Ziwei Li,Yarong Zhao,Huan Zhang,Thomas D Gallup,Jong Hoon Ha,Shiyan Dong,Yifan Wang,Wen-Jing Lu,Eman Bahrani,Ly James Lee,Lesheng Teng,Wen Jiang,Feng Lan,Betty Y.S. Kim,Andrew S. Lee +28 more
TL;DR: In this article , extracellular vesicles (EVs) produced via cellular nanoporation from human dermal fibroblasts, and encapsulating mRNA encoding for extracellular-matrix α1 type-I collagen (COL1A1) induced the formation of collagen-protein grafts and reduced wrinkle formation in the collagen-depleted dermal tissue of mice with photoaged skin.
Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia.
Adrienne M. Dorrance,Paolo Neviani,Gregory Ferenchak,X. Huang,Deedra Nicolet,Deedra Nicolet,Kati Maharry,Kati Maharry,Hatice Gulcin Ozer,P Hoellarbauer,Jihane Khalife,E B Hill,M Yadav,Brad Bolon,Robert J. Lee,Ly James Lee,Carlo M. Croce,Carlo M. Croce,Ramiro Garzon,Ramiro Garzon,Michael A. Caligiuri,Clara D. Bloomfield,Guido Marcucci +22 more
TL;DR: It is suggested that by targeting a single miR, that is, miR-126, it is possible to interfere with LSC activity, thereby opening potentially novel therapeutic approaches to treat AML patients.
Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma.
Mengzi Zhang,Xiaoju Zhou,Xiaoju Zhou,Bo Wang,Bryant C. Yung,Ly James Lee,Kalpana Ghoshal,Robert J. Lee +7 more
TL;DR: Proposed application of Lac-GLN as a liver-specific delivery vehicle for anti-miR therapy is suggested, based on results in mice and humans.
84
Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3 -ITD acute myeloid leukemia
Jihane Khalife,Hanna S. Radomska,Ramasamy Santhanam,Xiaomeng Huang,Paolo Neviani,Jennifer N. Saultz,Huating Wang,Yue-Zhong Wu,Houda Alachkar,Mirela Anghelina,Adrienne M. Dorrance,John Curfman,Clara D. Bloomfield,Bruno C. Medeiros,Danilo Perrotti,Ly James Lee,Robert J. Lee,Michael A. Caligiuri,Flavia Pichiorri,Carlo M. Croce,Ramiro Garzon,Monica L. Guzman,Jason H. Mendler,Guido Marcucci +23 more
TL;DR: The study demonstrates the potential of miR-155 as a novel therapeutic target in AML via pharmacologic interference with NF-κB-dependent regulatory mechanisms, and shows the targeting of this oncogenic microRNA with MLN4924, a compound presently being evaluated in clinical trials inAML.